Corrigendum: Increased Expression of sST2 in Early HIV Infected Patients Attenuated the IL-33 Induced T Cell Responses

Xian Wu, Li Yao, Cheng-Bo Song, Yali Chen, Yajing Fu, Yongjun Jiang, Haibo Ding, Hong Shang, Zining ZhangFrontiers in Immunology 2020 · DOI · OpenAlex

Abstract

This corrigendum corrects a graphical error in the original publication (DOI: 10.3389/fimmu.2018.02850). The study investigates the role of the IL-33/ST2 signaling pathway in modulating CD8+ T cell responses in HIV-1 infected patients, demonstrating that IL-33 acts as a potent adjuvant to enhance antiviral cytokine production. The findings suggest that while IL-33 can significantly boost immune responses, this effect may be naturally attenuated by the soluble decoy receptor sST2.

Introduction

In the context of HIV infection, CD8+ "killer" T cells—the body's primary defense against the virus—often become exhausted or inefficient. Researchers are investigating the IL-33/ST2 signaling pathway as a potential mechanism to "re-arm" these cells. IL-33 is an alarmin cytokine that binds to the ST2 receptor on immune cells to activate them. However, a soluble decoy version of this receptor, sST2, can sequester IL-33 in the blood, preventing it from reaching its target cells. This study explores whether exogenous IL-33 can overcome this inhibition to boost the production of Interferon-gamma (IFN-$\gamma$), a critical cytokine used by T cells to inhibit viral replication.

Methodology

The researchers utilized primary biological samples from a cohort of HIV-1 infected patients to test the effects of IL-33 in vitro:

  • Cell Isolation: CD8+ T cells were isolated from chronically infected individuals.
  • Antigen Stimulation: Cells were stimulated with peptide pools: Gag (HIV-specific) and CEF (a control pool from CMV, EBV, and Influenza).
  • Cytokine Treatment: Recombinant human IL-33 was added at concentrations of 0, 10, and 100 ng/mL to observe dose-response effects.
  • Assays: Flow cytometry was used to measure intracellular IFN-$\gamma$ expression, while ELISPOT assays quantified the total number of IFN-$\gamma$ secreting cells (SFCs).

Results and Correction

The primary purpose of this corrigendum is to rectify a duplication error in the flow cytometry plots of the original Figure 2C. The corrected data confirms the study's original conclusions: IL-33 significantly enhances T cell potency in a dose-dependent manner.

Figure 2: Corrected data showing IL-33 enhances IFN-γ production in CD8+ T cells. Panels A-D display flow cytometry and summary statistics for Gag and CEF stimulation. Panels E-F show ELISPOT quantification of secreting cells.

Key quantitative findings from the corrected figure include:

  • Gag-specific response: The percentage of IFN-$\gamma$ producing CD8+ T cells rose from a baseline of 2.44% to 7.81% when treated with 100 ng/mL of IL-33.
  • CEF-specific response: In the control group, the response increased from 1.81% to 5.80%.
  • Statistical Significance: ELISPOT data (Panels E and F) showed highly significant increases in secreting cells ($p=0.002$ for Gag stimulation), reinforcing the flow cytometry results and confirming that the visual error did not impact the scientific validity of the study.

Discussion and Future Directions

The study identifies IL-33 as a potent adjuvant that specifically enhances the response of T cells to viral antigens they are already programmed to recognize. The clear dose-dependency suggests that therapeutic IL-33 could restore immune function. However, the high levels of the decoy receptor sST2 found in early HIV patients present a significant clinical challenge. Future work must investigate strategies to bypass or block sST2 to allow IL-33 to effectively boost the immune system in vivo and potentially reduce viral load.

Summary updated

Abstract

[This corrects the article DOI: 10.3389/fimmu.2018.02850.].
BibTeX
@inproceedings{wu2020corrigendum,
  author = {Xian Wu and Li Yao and Cheng-Bo Song and Yali Chen and Yajing Fu and Yongjun Jiang and Haibo Ding and Hong Shang and Zining Zhang},
  title = {{Corrigendum: Increased Expression of sST2 in Early HIV Infected Patients Attenuated the IL-33 Induced T Cell Responses}},
  booktitle = {Frontiers in Immunology},
  year = {2020},
  doi = {10.3389/fimmu.2020.00088},
}
Figure